- Home
- PSNL vs BCYC Comparison
PSNL vs BCYC Comparison
Compare PSNL & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- BCYC
- Stock Information
- Founded
- PSNL 2011
- BCYC 2009
- Country
- PSNL United States
- BCYC United Kingdom
- Employees
- PSNL N/A
- BCYC N/A
- Industry
- PSNL Medical Specialities
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- BCYC Health Care
- Exchange
- PSNL Nasdaq
- BCYC Nasdaq
- Market Cap
- PSNL 576.8M
- BCYC 566.5M
- IPO Year
- PSNL 2019
- BCYC 2019
- Fundamental
- Price
- PSNL $6.59
- BCYC $7.04
- Analyst Decision
- PSNL Strong Buy
- BCYC Buy
- Analyst Count
- PSNL 5
- BCYC 10
- Target Price
- PSNL $8.00
- BCYC $25.00
- AVG Volume (30 Days)
- PSNL 1.6M
- BCYC 272.6K
- Earning Date
- PSNL 08-06-2025
- BCYC 08-05-2025
- Dividend Yield
- PSNL N/A
- BCYC N/A
- EPS Growth
- PSNL N/A
- BCYC N/A
- EPS
- PSNL N/A
- BCYC N/A
- Revenue
- PSNL $85,694,000.00
- BCYC $25,722,000.00
- Revenue This Year
- PSNL $0.45
- BCYC $7.35
- Revenue Next Year
- PSNL $25.75
- BCYC N/A
- P/E Ratio
- PSNL N/A
- BCYC N/A
- Revenue Growth
- PSNL 15.57
- BCYC N/A
- 52 Week Low
- PSNL $1.14
- BCYC $6.10
- 52 Week High
- PSNL $7.20
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- PSNL 69.33
- BCYC 35.17
- Support Level
- PSNL $6.27
- BCYC $6.87
- Resistance Level
- PSNL $7.03
- BCYC $7.59
- Average True Range (ATR)
- PSNL 0.43
- BCYC 0.42
- MACD
- PSNL 0.00
- BCYC -0.08
- Stochastic Oscillator
- PSNL 66.29
- BCYC 8.76
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.